A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer.
Some reports have evaluated the prognostic relevance of microRNAs (miRNAs) in patients with pancreatic cancer (PC). However, most studies focused on limited miRNAs with small number of patients. The aim of the study is to identify a panel of miRNA signature that could predict prognosis in PC with the data from The Cancer Genome Atlas (TCGA). A total of 167 PC patients with the corresponding clinical data were enrolled in our study. The miRNAs significantly associated with overall survival (OS) in PC patients were identified with Cox proportional regression model. A risk score formula was developed to evaluate the prognostic value of the miRNA signature in PC. Thirteen miRNAs were identified to be significantly related with OS in PC patients. Patients with high risk score suffered poor overall survival compared with patients who had low risk score. The multivariate Cox regression analyses showed that the miRNA signature could act as an independent prognostic indicator. In addition, the signature might serve as a predicator for treatment outcome. Our study identified a miRNA signature including 13 miRNAs which could serve as an independent marker in prognosis of PC.
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Xin
X
Zhou
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Zebo
Z
Huang
Department of Thoracic Surgery, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210029, China.
Lei
L
Xu
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Mingxia
M
Zhu
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Lan
L
Zhang
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Huo
H
Zhang
Department of Pathology, Sir Run Run Hospital Affiliated With Nanjing Medical University, Nanjing 211166, China.
Xiaping
X
Wang
Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China.
Hai
H
Li
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Wei
W
Zhu
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.|Cancer Center of Nanjing Medical University, Nanjing 210029, China.
Yongqian
Y
Shu
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.|Cancer Center of Nanjing Medical University, Nanjing 210029, China.
Ping
P
Liu
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000032:analysis*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000401:mortality*; D011379:Prognosis; D016016:Proportional Hazards Models
D014408:Biomarkers, Tumor; D035683:MicroRNAs
biomarker; miRNA; pancreatic cancer; prognosis; signature